School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia (S.J.S., J.J.D.V., E.M.J.G.); and DMPK, Early Cardiovascular, Renal and Metabolism (U.J.) and Discovery Sciences (S.A.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, Australia (S.J.S., J.J.D.V., E.M.J.G.); and DMPK, Early Cardiovascular, Renal and Metabolism (U.J.) and Discovery Sciences (S.A.), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Drug Metab Dispos. 2020 Jun;48(6):432-437. doi: 10.1124/dmd.120.090555. Epub 2020 Apr 1.
Oxygen surrogates (OSs) have been used to support cytochrome P450 (P450) enzymes for diverse purposes in drug metabolism research, including reaction phenotyping, mechanistic and inhibition studies, studies of redox partner interactions, and to avoid the need for NADPH or a redox partner. They also have been used in engineering P450s for more cost-effective, NADPH-independent biocatalysis. However, despite their broad application, little is known of the preference of individual P450s for different OSs or the substrate dependence of OS-supported activity. Furthermore, the biocatalytic potential of OSs other than cumene hydroperoxide (CuOOH) and hydrogen peroxide (HO) is yet to be explored. Here, we investigated the ability of the major human drug-metabolizing P450s, namely CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2, to use the following OSs: HO, tert-butyl hydroperoxide (-BuOOH), CuOOH, (diacetoxyiodo)benzene, and bis(trifluoroacetoxy)iodobenzene. Overall, CuOOH and -BuOOH were found to be the most effective at supporting these P450s. However, the ability of P450s to be supported by OSs effectively was also found to be highly dependent on the substrate used. This suggests that the choice of OS should be tailored to both the P450 and the substrate under investigation, underscoring the need to employ screening methods that reflect the activity toward the substrate of interest to the end application. SIGNIFICANCE STATEMENT: Cytochrome P450 (P450) enzymes can be supported by different oxygen surrogates (OSs), avoiding the need for a redox partner and costly NADPH. However, few data exist comparing relative activity with different OSs and substrates. This study shows that the choice of OS used to support the major drug-metabolizing P450s influences their relative activity and regioselectivity in a substrate-specific fashion and provides a model for the more efficient use of P450s for metabolite biosynthesis.
氧代试剂(OS)已被用于支持细胞色素 P450(P450)酶在药物代谢研究中的多种用途,包括反应表型分析、机制和抑制研究、氧化还原伴侣相互作用研究以及避免需要 NADPH 或氧化还原伴侣。它们还被用于工程 P450 以实现更具成本效益、不依赖 NADPH 的生物催化。然而,尽管它们有广泛的应用,但是对于个体 P450 对不同 OS 的偏好或 OS 支持的活性的底物依赖性知之甚少。此外,除过氧化环己酮(CuOOH)和过氧化氢(HO)之外的 OS 的生物催化潜力尚未得到探索。在这里,我们研究了主要的人药物代谢 P450,即 CYP3A4、CYP2C9、CYP2C19、CYP2D6 和 CYP1A2,使用以下 OS 的能力:HO、叔丁基过氧化物(-BuOOH)、CuOOH、(二乙酰氧基碘)苯和双(三氟乙酰氧基)碘苯。总体而言,CuOOH 和 -BuOOH 被发现最有效地支持这些 P450。然而,还发现 P450 被 OS 有效支持的能力也高度依赖于所用的底物。这表明 OS 的选择应该根据研究中的 P450 和底物进行调整,这突显了需要采用反映与最终应用相关的底物活性的筛选方法。
细胞色素 P450(P450)酶可以通过不同的氧代试剂(OS)来支持,从而避免需要氧化还原伴侣和昂贵的 NADPH。然而,比较不同 OS 与底物的相对活性的数据很少。本研究表明,用于支持主要药物代谢 P450 的 OS 的选择以底物特异性的方式影响它们的相对活性和区域选择性,并为更有效地利用 P450 进行代谢物生物合成提供了模型。